Literature DB >> 2234331

Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee.

W H Lee1.   

Abstract

A permanent malignant meningioma (MM) cell line of the human brain designated "IOMM-Lee" is reported. This cell line was successfully established from the tumor of a 61-year-old Chinese man with repeated recurrent primary intraosseous malignant meningioma of the skull. It has been subcultured for more than 60 passages during the past 30 months. The doubling time of cultured cells is approximately 62 hours. Tumorigenicity in athymic nude mice (Balb/c-nu/nu) who develop multiple pulmonary metastases was observed; the doubling time of tumor volume in vivo is approximately 5 days. Karyotypic analysis revealed this cell line to be of human origin and near-diploid, with a modal chromosome number of 49. The mesenchymal tumor marker vimentin and intracytoplasmic microfilaments were identified in the cytoplasm of tumor cells by indirect immunohistochemical peroxidase-anti-peroxidase assays and immunogold ultrastructural localization by transmission electron microscopy, respectively. Scanning electron microscopy of cultured cells and xenografted tumors revealed ellipsoidal or carrot-shaped tumor cells presenting a wrinkled surface with short sparse microvilli. Potential proliferating activity was determined by Ki-67 monoclonal antibody; the Ki-67 labeling index of cultured cells and xenografted tumors was approximately 36% and 30%, respectively. This newly established malignant meningioma cell line of the human brain may prove useful as a research model.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2234331

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  27 in total

1.  Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells.

Authors:  Venkateswara Rao Gogineni; Arun Kumar Nalla; Reshu Gupta; Dzung H Dinh; Jeffrey D Klopfenstein; Jasti S Rao
Journal:  Cancer Lett       Date:  2011-09-06       Impact factor: 8.679

Review 2.  Meningioma mouse models.

Authors:  Michel Kalamarides; Matthieu Peyre; Marco Giovannini
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

Review 3.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

4.  A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.

Authors:  Fares Nigim; Juri Kiyokawa; Alessandra Gurtner; Yoichiro Kawamura; Lingyang Hua; Ekkehard M Kasper; Priscilla K Brastianos; Daniel P Cahill; Samuel D Rabkin; Robert L Martuza; W Shawn Carbonell; Hiroaki Wakimoto
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

5.  A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Authors:  Fares Nigim; Shin-Ichi Esaki; Michael Hood; Nina Lelic; Marianne F James; Vijaya Ramesh; Anat Stemmer-Rachamimov; Daniel P Cahill; Priscilla K Brastianos; Samuel D Rabkin; Robert L Martuza; Hiroaki Wakimoto
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

6.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

Review 7.  The biology of meningiomas.

Authors:  I E McCutcheon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

8.  Tissue transgluaminase 2 expression in meningiomas.

Authors:  Liya Yuan; Amir Behdad; Matthew Siegel; Chaitan Khosla; Ryuji Higashikubo; Keith M Rich
Journal:  J Neurooncol       Date:  2008-06-28       Impact factor: 4.130

9.  The treatment of malignant meningioma with verotoxin.

Authors:  Bodour Salhia; James T Rutka; Clifford Lingwood; Anita Nutikka; Wouter R Van Furth
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

10.  A genetic strategy to overcome the senescence of primary meningioma cell cultures.

Authors:  Gilson S Baia; Alison L Slocum; Jeanette D Hyer; Anjan Misra; Nouzhan Sehati; Scott R VandenBerg; Burt G Feuerstein; Dennis F Deen; Michael W McDermott; Anita Lal
Journal:  J Neurooncol       Date:  2006-03-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.